AbbVie Inc (ABBV)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $453.12B
Last updated: Sep 01, 2026 at 5:00 PM ET
Earnings
Performance (10Y)
Upcoming Estimates
Dividends
Dividend Metrics
Growth
Key Metrics
Technical Indicators Dashboard
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Data
Related GNG Research
Starting Over: The 15-Stock Dividend Portfolio My Own Rules Would Build
TOLL+M disciplined 15-stock build: 15 holdings, average forward yield >=3%, one name per sleeve, no manager overrides Toll-road core via EPD and WMB - EPD yields ~6%, 27-year increase streak, DCF coverage >1.6x; WMB grows faster but has a 2016 cut scar Real-asset income engines: UNP (rail oligopoly), CME (exchanges), LMT (defense, payout mid-60s, long backlog), VICI and Realty Income - O has 30+ years of raises Framework fills gaps: NextEra - dividend +10% last year, payout ~40%; PepsiCo - yield >4% and 50+ years of raises; TXN and AbbVie meet TOLL+M thresholds Investor playbook: one-per-sector diversification, target >=3% avg forward yield, score holdings with TOLL+M, avoid concentration, add sleeves for higher income or themes
The Intelligent Compounder's Playbook: Five Dividend Aristocrats Built to Outlast the Next Downturn
Five dividend aristocrats stress-tested across 170+ quality metrics, ranked by conviction GNG Safety Scores span from 70.47 to a perfect 100 across the final five picks One insurer just posted record combined ratios and landed a $20B government contract The "cheapest" candidate on the screen carried an 876% payout ratio and got cut A 100th-percentile cash flow predictor is trading below its own recent average multiple The tactical value pick yields 3.9% with 8.58% FCF yield while margins normalize
Pfizer: The 6% Yield Hiding Behind a Post-Pandemic Hangover
Pfizer trades at 9.6x forward earnings with 6.3% yield; non-COVID portfolio grew 6% operationally in 2025, but market still prices post-pandemic discount GAAP payout ratio of 98.8% is misleading; on adjusted EPS of $3.22, actual payout is 53%. The $4.4B Seagen impairment distorts GAAP picture Metsera obesity pipeline (Phase 2b: 12.3% weight loss, monthly dosing) is unpriced optionality at current multiples; ten Phase 3 trials launch 2026 Morningstar cut fair value from $34 to $32 post-Q4; Stock Rover FV $34.57. Blended upside of 13-16% before dividends in base case Quality Score 85/100, Piotroski 7, Beneish M-Score -2.38. ROIC-WACC spread positive at +190 bps. Balance sheet is not the risk here Five explicit risks quantified: GAAP payout tightness, $1.5B LOE headwind, negative revision momentum, Metsera execution risk, policy headwinds Conditional BUY for income/value accounts with staged sizing at 0.5-1.0%; trim at $33-36; invalidation on dividend cut or two sub-$0.65 adj EPS quarters
The Income Fortress: Building a 3.5% Yield Without the Usual Landmines
3.5% yield with 68% avg payout ratio vs typical high-yield portfolios at 95%+ - sustainability over maximum income Systematic filtering: 6,000 stocks → 27 survivors through 5-pillar scoring (Income, Safety, Growth, Risk, Valuation) Growth ballast strategy: MSFT's 0.9% yield @ 10% growth beats 5% yield @ 3% growth by year seven Energy concentration at 29% with built-in safety: EOG profitable at $40 oil vs current $75 = $35/barrel cushion Five quantified risk scenarios with probabilities: China slowdown (40%), currency headwinds (45%), energy crash (25%) Diversification shield: 9 sectors, 12 countries, 62% US/38% international - no single point of failure Quarterly rebalancing on GNG Research: systematic 1.5% drift triggers, invalidation rules, tax optimization
Government Contracts
Top agency: Department of Defense at 98.6% of trailing twelve month obligations across 2 agencies
Recent Awards
Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.
News
Frequently Asked Questions About ABBV
- What is ABBV's current dividend yield?
- AbbVie Inc (ABBV) has a current dividend yield of 2.66%.
- Does ABBV pay dividends?
- Yes, AbbVie Inc pays dividends with a current yield of 2.66%.
- What is ABBV's P/E ratio?
- AbbVie Inc has a price-to-earnings (P/E) ratio of 23.59.
- What is ABBV's market cap?
- AbbVie Inc (ABBV) has a market capitalization of $453.12B with a current stock price of $256.38.
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.